Drug Trial Radar · NCT05271604
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Dec 13, 2022
Primary completion
Sep 22, 2025
Study completion Sep 22, 2025
Sponsor
- Lead sponsor
- BioAtla, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label Phase 2 study designed to evaluate the efficacy and safety of BA3021 as monotherapy and combination therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Conditions
- Head and Neck Cancer
- Squamous Cell Carcinoma of Head and Neck
- Recurrent Squamous Cell Carcinoma of the Head and Neck
- Metastatic Cancer
- Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
Ozuriftamab VedotinBiological
Conditionally active biologic anti-ROR2 antibody drug conjugate
PembrolizumabBiological
PD-1 inhibitor
Evalstotug (BA3071)Biological
Conditionally active biologic anti-CTLA-4 checkpoint blockade antibody
CetuximabBiological
Epidermal growth factor receptor (EGFR) antagonist
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR) per RECIST v1.1Time frame: Up to 24 months
- Incidence of Adverse Events or Serious Adverse Events as assessed by CTCAE v5Time frame: Up to 24 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California
Christiana Care Helen Graham Cancer Center
Newark, Delaware
Northwestern University
Chicago, Illinois
Norton Cancer Institute
Louisville, Kentucky
Washington University Medical Siteman Cancer Center
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.